Evidence map›Paper›PMID 42431962›Full record

ArticleScientific reports2026

Intestinal FXR deficiency uncouples steatosis protection from liver inflammation and fibrosis in MASH-diet fed mice.

Margaux Nawrot, Simon Peschard, Morgane M Thibaut, Kévin Ory, Emmanuelle Vallez, Emilie Dorchies, Véronique Touche, Julie Dubois-Chevalier, Céline Gheeraert, Sandrine Caron and 9 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Margaux Nawrot *Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France. margaux.nawrot@inserm.fr.ORCID http://orcid.org/0000-0003-4442-7180
Simon Peschard *Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Morgane M ThibautMetabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, UCLouvain, Brussels, Belgium.
Kévin OryUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Emmanuelle VallezUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Emilie DorchiesUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Véronique ToucheUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Julie Dubois-ChevalierUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Céline GheeraertUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Sandrine CaronUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Kadiombo BantubungiUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Philippe LefebvreUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Anne TailleuxUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Joel T HaasUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Laure B BindelsMetabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, UCLouvain, Brussels, Belgium.
Isabelle LeclercqLaboratory of Hepato-Gastroenterology, Institute of Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium.
David DombrowiczUniv. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Sophie Lestavel *Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France.
Bart Staels *Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Inserm, Lille, F- 59000, France. bart.steals@pasteur-lille.fr.

Funding

Agence Nationale de la Recherche ANR-16-RHUS-0006 PreciNASHAgence Nationale de la Recherche DeCodeNASH (ANR-20-CE14-0034)European Research Council ERC Immunobile n°694717European Research Council ERC-StG Metabo3DC (101042759)Université de Lille I-SITE ULille Young Researcher Grant (R-JEUNES-19-006)
6 · The paper itself

Abstract

The Farnesoid X Receptor (FXR), a nuclear bile acid (BA) receptor highly expressed in the liver and intestine, is a potential pharmacological target for Metabolic dysfunction-Associated SteatoHepatitis (MASH). While intestinal FXR inhibition reduces high-fat diet (HFD)-induced hepatic steatosis, its role in MASH progression remains unclear. This study investigates the impact of intestinal FXR-deficiency on MASH development in a diet-induced murine model. Intestinal FXR-deficient (

Indexed as

FXRIntestine-liver crosstalkLiver inflammationLiver steatosis protectionMASH

Identifiers

PMID42431962
PMCPMC13654801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.